Concord Biotech Limited (NSE: CONCORDBIO)

India flag India · Delayed Price · Currency is INR
2,151.05
+15.15 (0.71%)
Dec 24, 2024, 3:30 PM IST
42.96%
Market Cap 225.03B
Revenue (ttm) 10.86B
Net Income (ttm) 3.28B
Shares Out 104.62M
EPS (ttm) 31.35
PE Ratio 68.61
Forward PE 52.10
Dividend 8.75 (0.41%)
Ex-Dividend Date n/a
Volume 24,792
Open 2,128.25
Previous Close 2,135.90
Day's Range 2,099.90 - 2,182.00
52-Week Range 1,327.05 - 2,664.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 10, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1984
Employees 1,377
Stock Exchange National Stock Exchange of India
Ticker Symbol CONCORDBIO
Full Company Profile

Financial Performance

In 2023, Concord Biotech's revenue was 10.17 billion, an increase of 19.20% compared to the previous year's 8.53 billion. Earnings were 3.08 billion, an increase of 28.33%.

Financial Statements

News

There is no news available yet.